Mustang Bio, Inc. (MBIO)
| Market Cap | 4.53M +22.4% |
| Revenue (ttm) | n/a |
| Net Income | -2.72M |
| EPS | -0.46 |
| Shares Out | 7.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,984 |
| Open | 0.6300 |
| Previous Close | 0.6055 |
| Day's Range | 0.5802 - 0.6300 |
| 52-Week Range | 0.5306 - 7.0000 |
| Beta | 2.11 |
| Analysts | Buy |
| Price Target | 100.00 (+16,625.21%) |
| Earnings Date | May 5, 2026 |
About MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for MBIO stock is "Buy" and the 12-month stock price target is $100.0.
News
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Co...
IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.
This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may...
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection
Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp...
Mustang Bio granted orphan drug designation by FDA for MB-101
Mustang Bio (MBIO) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Mustang for MB-101 for the treatment of recurrent diffuse and anaplastic astrocytoma and…
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting ...
Mustang Bio treatment of malignant glioma granted orphan designation
Mustang Bio’s (MBIO) treatment of malignant glioma was granted FDA orphan designation, according to a post to the agency’s website.
Mustang Bio regains compliance with Nasdaq requirement
Mustang Bio (MBIO) announced that it has received notice from Nasdaq informing the company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as ...
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”)...
Mustang Bio exits lease for Massachusetts facility, divests equipment
Mustang Bio (MBIO) announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to Abb...
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical break...
Mustang Bio regains compliance with Nasdaq
Mustang Bio (MBIO) announced that it has received notice from Nasdaq informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550…
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”...
Mustang Bio Announces Closing of $8 Million Public Offering
WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio prices 2.66M shares at $3.01 in public offering
Mustang Bio (MBIO) announced the pricing of a public offering of an aggregate of 2,657,807 shares of its common stock, Series C-1 warrants to purchase up to 2,657,807 shares of…
Mustang Bio Announces Pricing of $8 Million Public Offering
WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio trading halted, news pending
19:50 EST Mustang Bio (MBIO) trading halted, news pending
Mustang Bio files to sell common stock and warrants, no amount given
16:20 EST Mustang Bio (MBIO) files to sell common stock and warrants, no amount given
Mustang Bio announces 1-for-50 reverse stock split
Mustang Bio (MBIO) announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. Mustang expects its common stock to begin trading on a…
Mustang Bio Announces Reverse Stock Split
WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio files to sell 34.77M shares of common stock for holders
The company will not receive any of the proceeds from the sale of the shares by the selling stockholders.
Mustang Bio receives positive listing determination from Nasdaq
Mustang Bio (MBIO) announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for…
Mustang Bio Receives Positive Listing Determination from Nasdaq
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio granted Orphan Drug Designation by U.S. FDA for MB-108
Mustang Bio (MBIO) announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation to Mustang for MB-108, a herpes simplex virus type 1 oncolytic virus, for…
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...